$PALI
Palisade Bio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$1.39
▼-1.77%-$0.025
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonatePalisade Bio, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is PALI down today? It is at $1.39 (-1.77%), and our scanner flagged it 128 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment PALI spikes, and full due diligence on PALI — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $PALI 128 times in the last 30 days. Create a free account to track $PALI, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
PALI is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on PALI today, peaking at 7.7x its normal volume.
Likely catalystPalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentReported In the FSCD cohort, PALI-2108 reduced mean SES-CD score by approximately 47.5% (a 3.8-point improvement), with 2 out of 5 patients achieving both endoscopic response and remission based on SES-CD.Reported Net loss was $10.6 million, or a net loss of $0.05 per share, for the three months ended June 30, 2026, compared to a net loss of $2.8 million, or a net loss of $0.58 per share, for the three months ended June 30, 2025.Reported Series A Convertible Preferred Stock, $0.01 par value,, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Oct 8, 2026 · 11 days agoThe company is cleared to issue new shares on demand, but has not yet. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Active shelf on file — the company can issue new shares on demand (valid ~3 years)
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Finley John David Officer | Sold (automatic/other) | -1.41M 0.8% of company | sold 42% | 1.94M | $2.1M at $1.49 | Oct 6, 26 |
Finley John David Officer | Other | 3.23M 1.9% of company | added 100% | 3.36M | n/a | Oct 6, 26 |
Jones Mitchell Lawrence Officer | Sold (automatic/other) | -1.03M 0.6% of company | sold 38% | 1.68M | $1.5M at $1.49 | Oct 6, 26 |
Jones Mitchell Lawrence Officer | Other | 2.62M 1.5% of company | added 100% | 2.71M | n/a | Oct 6, 26 |
Williams Donald Allen Director | Bought (open market) | +10K | added 0.6% | 1.59M | $15K at $1.46 | Oct 2, 26 |
Williams Donald Allen Director | Bought (open market) | +10K | added 0.6% | 1.58M | $14K at $1.42 | Oct 1, 26 |
Finley John David Officer | Sold (automatic/other) | -88K 0.05% of company | sold 41% | 129K | n/a | Aug 19, 26 |
Finley John David Officer | Acquired (grant/award) | +88K 0.05% of company | added 100% | 88K | n/a | Aug 19, 26 |
Baltera Robert Jr. Director | Bought (open market) | +25K 0.01% of company | added 5.7% | 462K | $49K at $1.96 | Jul 9, 26 |
Baltera Robert Jr. Director | Bought (open market) | +20K 0.01% of company | added 4.8% | 437K | $40K at $1.99 | Jul 8, 26 |
Finley John David Officer | Sold (automatic/other) | -147K 0.08% of company | sold 40% | 218K | $304K at $2.07 | Jul 7, 26 |
Finley John David Officer | Other | 133 | added <0.1% | 218K | $93 at $0.700 | Jul 7, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
PALI is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on PALI today, peaking at 7.7x its normal volume.
PALI last traded at $1.39, down 1.77% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Palisade Bio, Inc. Common Stock (PALI) is next expected to report earnings on Monday, November 9, 2026, about 22 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The PALI Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged PALI 128 times in the last 30 days.
PALI (Palisade Bio, Inc. Common Stock) trades on XNAS, with a market cap of about $246M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge PALI for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$PALI discussion
Sign in to ask a question or join the discussion.